piperidines and Flatulence

piperidines has been researched along with Flatulence* in 6 studies

Reviews

1 review(s) available for piperidines and Flatulence

ArticleYear
[Meteorism and flatulence].
    Medizinische Monatsschrift fur Pharmazeuten, 1992, Volume: 15, Issue:12

    Topics: Cisapride; Colonic Diseases, Functional; Combined Modality Therapy; Flatulence; Gases; Humans; Intestines; Metoclopramide; Piperidines; Serotonin Antagonists

1992

Trials

4 trial(s) available for piperidines and Flatulence

ArticleYear
Selective postoperative inhibition of gastrointestinal opioid receptors.
    The New England journal of medicine, 2001, Sep-27, Volume: 345, Issue:13

    Postoperative recovery of gastrointestinal function and resumption of oral intake are critical determinants of the length of hospital stay. Although opioids are effective treatments for postoperative pain, they contribute to the delayed recovery of gastrointestinal function.. We studied the effects of ADL 8-2698, an investigational opioid antagonist with limited oral absorption that does not readily cross the blood-brain barrier, on postoperative gastrointestinal function and the length of hospitalization. We randomly assigned 79 patients--including 1 whose surgery was canceled--to receive one capsule containing 1 mg or 6 mg of ADL 8-2698 or an identical-appearing placebo capsule two hours before major abdominal surgery and then twice daily until the first bowel movement or until discharge from the hospital. Data were analyzed for 26 patients in each of the three groups; all received opioids for postoperative pain relief. Observers who were unaware of the group assignments evaluated the outcomes.. Fifteen patients underwent partial colectomy and 63 underwent total abdominal hysterectomy. Patients given 6 mg of ADL 8-2698 had significantly faster recovery of gastrointestinal function than those given placebo. The median time to the first passage of flatus decreased from 70 to 49 hours (P=0.03), the median time to the first bowel movement decreased from 111 to 70 hours (P=0.01), and the median time until patients were ready for discharge decreased from 91 to 68 hours (P=0.03). Effects in the group that received 1 mg of ADL 8-2698 were less pronounced.. Selective inhibition of gastrointestinal opioid receptors by an antagonist with limited oral absorption that does not readily cross the blood-brain barrier speeds recovery of bowel function and shortens the duration of hospitalization.

    Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Colectomy; Defecation; Digestive System; Female; Flatulence; Humans; Hysterectomy; Intestinal Obstruction; Length of Stay; Male; Meperidine; Middle Aged; Morphine; Narcotic Antagonists; Pain, Postoperative; Piperidines; Postoperative Complications; Receptors, Opioid; Time Factors

2001
The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease.
    Scandinavian journal of gastroenterology, 1997, Volume: 32, Issue:11

    Successful treatment of gastro-oesophageal reflux disease (GORD) has traditionally been assessed as healing of reflux oesophagitis, which may not be relevant in patients with moderate disease. In these patients symptom relief and patient satisfaction with therapy are of fundamental importance. Cisapride has well-documented prokinetic effects and may be well suited for long-term therapy of GORD, but its effectiveness in purely symptomatic treatment is unknown. We therefore compared two dosage regimens of cisapride with placebo over a period of 6 months in patients with evidence of gastrooesophageal reflux, initially treated with antisecretory medication, with regard to maintaining symptom relief and satisfaction with treatment.. Five hundred and thirty-five patients with reflux oesophagitis grade 1 (n = 293) or 2 (n = 124) or with no reflux oesophagitis but pathologic 24-h pH-metry (n = 118) achieved satisfactory symptom relief with an H2-receptor antagonist or proton pump inhibitor within 4-8 weeks. In a double-blind randomized, parallel-group study, they were then treated with cisapride, 20 mg at night or 20 mg twice daily, or placebo and followed up for a maximum period of 6 months. Relapse was defined as dissatisfaction with therapy or an average consumption of more than two antacid tablets a day.. Median time to relapse was 63 days for cisapride, 20 mg twice daily; 59 days for cisapride, 20 mg at night; and 49 days for placebo. Time to relapse was not significantly different (P = 0.09). Presence and grade of oesophagitis at base line, type of therapy before randomization, and pattern of non-reflux symptoms at base line did not influence these findings significantly.. The study indicates that cisapride is of limited value in maintenance therapy of GORD in patients in whom symptom relief has been accomplished with potent antisecretory medication. This 'step-down' approach to therapy seems disadvantageous in the long-term therapy of GORD.

    Topics: Abdominal Pain; Cisapride; Constipation; Diarrhea; Drug Administration Schedule; Endoscopy; Esophagitis, Peptic; Female; Flatulence; Gastroesophageal Reflux; Gastrointestinal Agents; Heartburn; Humans; Male; Middle Aged; Piperidines; Recurrence; Remission Induction; Severity of Illness Index; Time Factors

1997
"Prokinetic" treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride.
    Journal of clinical gastroenterology, 1991, Volume: 13, Issue:1

    The effects of prokinetic treatment with cisapride in patients with constipation-predominant irritable bowel syndrome (IBS) were evaluated in a randomized, double-blind, placebo-controlled study. Sixty-nine IBS patients were assigned to a 12-week treatment with either 5 mg cisapride or placebo t.i.d.; this dosage could be changed if necessary. The mean weekly number of days on which a stool was passed in the cisapride and placebo group increased to 5.3 and 4.4 (p less than 0.05) during weeks 8-12 of treatment, and the number of days with stools of normal consistency increased to 3.5 and 1.9 (p less than 0.05), respectively. At week 12, the reduction in severity and frequency scores for abdominal pain was significantly greater (p less than or equal to 0.05) in the cisapride group (60 and 61%) than in the placebo group (40 and 32%), as it was for abdominal distension (p less than 0.05). Cisapride tended to be better than placebo in diminishing flatulence. In 71% versus 39% of the patients the overall rating for the response to treatment was good or excellent at week 12. Cisapride was well tolerated. These results suggest that the drug will be useful for the management of constipation-predominant IBS.

    Topics: Abdominal Pain; Adolescent; Adult; Aged; Cisapride; Colonic Diseases, Functional; Constipation; Defecation; Double-Blind Method; Female; Flatulence; Gastrointestinal Motility; Humans; Male; Middle Aged; Piperidines

1991
Use of the peripheral dopamine antagonist, domperidone, in the management of gastro-intestinal symptoms in patients with irritable bowel syndrome.
    Current medical research and opinion, 1980, Volume: 6, Issue:9

    An evaluation was carried out of the effect of domperidone on gastro-intestinal symptoms in patients with irritable bowel syndrome. Ninety-eight patients were included; 32 in an open pilot study and 66 in a double-blind placebo-controlled study. Domperidone was taken at a dosage of 10 mg tablets 4-times daily. At the end of the 4-week treatment, symptoms had disappeared or were at least markedly improved in about 80% of the domperidone-treated patients. Significant superiority of domperidone to the placebo was observed for the symptom clusters 'post-prandial flatulence', 'abdominal pain' and 'abnormal bowel habit'. No side-effects were reported.

    Topics: Abdomen; Adult; Aged; Benzimidazoles; Clinical Trials as Topic; Colonic Diseases, Functional; Defecation; Domperidone; Double-Blind Method; Female; Flatulence; Humans; Male; Middle Aged; Pain; Pilot Projects; Piperidines; Placebos

1980

Other Studies

1 other study(ies) available for piperidines and Flatulence

ArticleYear
Donepezil and paroxetine: possible drug interaction.
    Journal of the American Geriatrics Society, 1999, Volume: 47, Issue:8

    Topics: Aged; Aggression; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Confusion; Diarrhea; Donepezil; Drug Interactions; Female; Flatulence; Humans; Indans; Male; Nootropic Agents; Paroxetine; Piperidines; Sleep Initiation and Maintenance Disorders

1999